Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kai-Chun, Ran, Zhi Hua, Gao, Xiang, Chen, Minhu, Zhong, Jie, Sheng, Jian-Qiu, Kamm, Michael A, Travis, Simon, Wallace, Kori, Mostafa, Nael M, Shapiro, Marisa, Li, Yao, Thakkar, Roopal B, Robinson, Anne M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863049/
https://www.ncbi.nlm.nih.gov/pubmed/27175116
http://dx.doi.org/10.5217/ir.2016.14.2.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863049/
https://www.ncbi.nlm.nih.gov/pubmed/27175116
http://dx.doi.org/10.5217/ir.2016.14.2.152

Ejemplares similares